(ASMB) Assembly Biosciences - Overview
Stock: Antiviral, Small-Molecule, Clinical-Stage, Capsid, Polymerase
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 65.9% |
| Relative Tail Risk | -12.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.27 |
| Alpha | 68.90 |
| Character TTM | |
|---|---|
| Beta | 0.998 |
| Beta Downside | 0.900 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.51% |
| CAGR/Max DD | 0.23 |
Description: ASMB Assembly Biosciences January 17, 2026
Assembly Biosciences Inc. (NASDAQ: ASMB) is a U.S. biotech focused on developing long-acting antivirals. Its lead pipeline comprises helicase-primase inhibitors (ABI-5336, ABI-1179) in Phase 1a/1b for recurrent genital herpes, a capsid-assembly modulator (ABI-4334) in Phase 1b for hepatitis B, an oral hepatitis D entry inhibitor (ABI-6250) in Phase 1a, and a broad-spectrum non-nucleoside polymerase inhibitor (ABI-7423) targeting transplant-related herpesviruses. The company maintains an option, license, and collaboration agreement with Gilead Sciences for virology R&D and operates out of South San Francisco, having rebranded from Ventrus Biosciences in 2014.
Key quantitative points (derived from the most recent Q3 2024 filing) include a market capitalization of roughly $500 million, cash and short-term investments of about $120 million, and annual R&D spend of $30 million, giving the firm roughly 4 years of runway at current burn rates. The viral-therapeutics sector is projected to grow at a CAGR of 10-12 % through 2030, driven by unmet needs in chronic hepatitis B/D and herpesvirus infections, which underpins the commercial upside of Assembly’s pipeline. The Gilead collaboration, while undisclosed in financial terms, is typical of early-stage biotech deals that provide milestone-linked funding and potential co-development rights, reducing downside risk for Assembly.
For a deeper quantitative comparison of ASMB’s valuation metrics, you may find the ValueRay platform a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -38.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -46.02 > 1.0 |
| NWC/Revenue: 493.2% < 20% (prev 199.7%; Δ 293.5% < -1%) |
| CFO/TA -0.23 > 3% & CFO -55.7m > Net Income -38.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.66m) vs 12m ago 20.54% < -2% |
| Gross Margin: 18.25% > 18% (prev 0.99%; Δ 1725 % > 0.5%) |
| Asset Turnover: 21.86% > 50% (prev 28.25%; Δ -6.39% > 0%) |
| Interest Coverage Ratio: -12.69 > 6 (EBITDA TTM -41.6m / Interest Expense TTM -3.29m) |
Altman Z'' -15.00
| A: 0.76 (Total Current Assets 236.8m - Total Current Liabilities 53.4m) / Total Assets 240.0m |
| B: -3.56 (Retained Earnings -854.1m / Total Assets 240.0m) |
| C: -0.25 (EBIT TTM -41.8m / Avg Total Assets 170.1m) |
| D: -14.91 (Book Value of Equity -854.2m / Total Liabilities 57.3m) |
| Altman-Z'' Score: -23.89 = D |
Beneish M 1.00
| DSRI: 16.15 (Receivables 912.0k/43.0k, Revenue 37.2m/28.3m) |
| GMI: 5.45 (GM 18.25% / 99.48%) |
| AQI: 0.42 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 1.31 (Revenue 37.2m / 28.3m) |
| TATA: 0.07 (NI -38.5m - CFO -55.7m) / TA 240.0m) |
| Beneish M-Score: 13.43 (Cap -4..+1) = D |
What is the price of ASMB shares?
Over the past week, the price has changed by +1.71%, over one month by -14.26%, over three months by -15.99% and over the past year by +91.67%.
Is ASMB a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ASMB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.8 | 82.1% |
| Analysts Target Price | 47.8 | 82.1% |
| ValueRay Target Price | 29.4 | 12.1% |
ASMB Fundamental Data Overview February 04, 2026
P/B = 2.2259
Revenue TTM = 37.2m USD
EBIT TTM = -41.8m USD
EBITDA TTM = -41.6m USD
Long Term Debt = 2.75m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 548.0k USD (from shortTermDebt, last quarter)
Debt = 2.75m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -19.8m USD (from netDebt column, last quarter)
Enterprise Value = 187.3m USD (417.1m + Debt 2.75m - CCE 232.6m)
Interest Coverage Ratio = -12.69 (Ebit TTM -41.8m / Interest Expense TTM -3.29m)
EV/FCF = -3.36x (Enterprise Value 187.3m / FCF TTM -55.8m)
FCF Yield = -29.78% (FCF TTM -55.8m / Enterprise Value 187.3m)
FCF Margin = -150.0% (FCF TTM -55.8m / Revenue TTM 37.2m)
Net Margin = -103.6% (Net Income TTM -38.5m / Revenue TTM 37.2m)
Gross Margin = 18.25% ((Revenue TTM 37.2m - Cost of Revenue TTM 30.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev -67.52%)
Tobins Q-Ratio = 0.78 (Enterprise Value 187.3m / Total Assets 240.0m)
Interest Expense / Debt = 22.11% (Interest Expense 609.0k / Debt 2.75m)
Taxrate = 21.0% (US default 21%)
NOPAT = -33.0m (EBIT -41.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.44 (Total Current Assets 236.8m / Total Current Liabilities 53.4m)
Debt / Equity = 0.02 (Debt 2.75m / totalStockholderEquity, last quarter 182.7m)
Debt / EBITDA = 0.48 (negative EBITDA) (Net Debt -19.8m / EBITDA -41.6m)
Debt / FCF = 0.35 (negative FCF - burning cash) (Net Debt -19.8m / FCF TTM -55.8m)
Total Stockholder Equity = 65.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -22.66% (Net Income -38.5m / Total Assets 240.0m)
RoE = -59.01% (Net Income TTM -38.5m / Total Stockholder Equity 65.3m)
RoCE = -61.35% (EBIT -41.8m / Capital Employed (Equity 65.3m + L.T.Debt 2.75m))
RoIC = -50.51% (negative operating profit) (NOPAT -33.0m / Invested Capital 65.3m)
WACC = 9.64% (E(417.1m)/V(419.9m) * Re(9.59%) + D(2.75m)/V(419.9m) * Rd(22.11%) * (1-Tc(0.21)))
Discount Rate = 9.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 18.17%
Fair Price DCF = unknown (Cash Flow -55.8m)
EPS Correlation: -62.74 | EPS CAGR: -5.33% | SUE: 1.70 | # QB: 1
Revenue Correlation: 89.14 | Revenue CAGR: 164.4% | SUE: 0.48 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.50 | Chg30d=+0.155 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-3.50 | Chg30d=-0.426 | Revisions Net=-1 | Growth EPS=+5.6% | Growth Revenue=-41.4%